The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Peptide drug development has made great progress in the last decade thanks to new
production, modification, and analytic technologies. Peptides have been produced and …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

SGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as
glucose lowering therapies, with additional benefits of weight loss and blood pressure …

Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

As one of the most successful therapeutic target families, G protein-coupled receptors
(GPCRs) have experienced a transformation from random ligand screening to knowledge …

Diabetes mellitus (DM) is a metabolic disorder that occurs in the body because of decreased
insulin activity and/or insulin secretion. Pathological changes such as nephropathy …

Diabesity is a term used to describe the combined adverse health effects of obesity and
diabetes mellitus. The worldwide dual epidemic of obesity and type 2 diabetes is an …

Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

Despite the successful development of new therapies for the treatment of type 2 diabetes,
such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose …